降钙素基因相关肽受体拮抗剂-Ubrogepent 的研究进展  

Research Progress in Ubrogepant

作　　者：赵爽[1] 陈红英 苗秋丽[1] 刘伟兵 宋燕青[1] ZHAO Shuang;CHEN Hongying;MIAO Qiuli;LIU Weibing;SONG Yanqing(Department of Pharmacy,the First Hospital of Jilin University,Changchun Jilin 130021,China)

机构地区：[1]吉林大学第一医院药学部,吉林长春130021

出　　处：《中国药物警戒》2021年第3期289-293,共5页Chinese Journal of Pharmacovigilance

基　　金：国家重点研发计划(2016YFC1303804)。

摘　　要：降钙素基因相关肽受体拮抗剂ubrogepant是一种口服、小分子、高选择性、降钙素基因相关肽受体拮抗剂。抑制降钙素基因相关肽(CGRP)的活性而发挥作用。与传统治疗偏头痛急性期的药物相比,ubrogepant可以有效预防急性偏头痛的发作,减少发作次数,且有良好的耐受性和较少的禁忌证。通过对ubrogepant的作用机制、药动学、药效学、临床评价和安全性等方面进行综述,为临床治疗和深入研究提供参考。Ubrogepant(trade name:Ubralvy)is an oral,small molecule,highly selective,calcitonin generelated peptide receptor antagonist(CGRP P-receptor),which won the first approval of FDA for the treatment of episodic migraine by inhibiting CRGP activity.Compared with conventional drugs for acute migraine,ubrogepant can prevent the episode of acute migraine and reduce the number of episodes,which is better tolerated and has fewer contraindications.This article reviews the mechanism,pharmacokinetics,pharmacodynamics,clinical evaluation and safety of ubrogepant in order toprovide reference for clinical treatment and further research.

关 键 词：降钙素基因相关肽受体拮抗剂 ubrogepant 急性偏头痛 小分子口服药物 

分 类 号：R994.13[医药卫生—毒理学]